12:37 PM EST - Cardiome Pharma Corp. : has reported positive results from a Phase 2b study of vernakalant, its drug to treat atrial fibrillation. 51 percent of 150 patients receiving 500-milligram doses of the drug completed the 90-day study with normal heart rhythm, compared with 37 percent of the 160 patients who received the placebo. Cardiome Pharma Corp.
shares T.COM are trading $2.21 at $10.60.
